Trial | Phase | TNM | Population | Regimen | Sample | RR |
---|---|---|---|---|---|---|
Chemotherapy | Â | Â | Â | Â | Â | Â |
Roth 1994 [21] | II | IIIA | Total | CEP | 28 | 35Â % |
Rosell 1994 [20] | II | IIIA | Total | MIC | 30 | – |
Scagliotti 2012 [19] (CHEST) | III | I-IIIA | Total | GC | 129 | 35.4Â % |
TKI | Â | Â | Â | Â | Â | Â |
Lara-Guerra 2009 [13] | II | I | Total | G | 36 | 11Â % |
 | II | I | Mut EGFR | G | 6 | 50 % |
Schaake 2012 [14] | II | I-IIIA | Total | E | 60 | 5Â % |
 | II | I-IIIA | Enriched | E | 29 | 34 % |
Chemo-TKI | Â | Â | Â | Â | Â | Â |
Lu 2013 [22] (CTONG 1101) | II | IIIA-N2 | Enriched | E + GC | 39 | 46 % |
Bio-maker guided | Â | Â | Â | Â | Â | Â |
Zhong 2014 (CSLC 0702) | II | IIIA-N2 | Total | E or GC | 24 | 42Â % |
II | IIIA-N2 | Mut EGFR | E | 12 | 58.3Â % | |
II | IIIA-N2 | WT-EGFR | GC | 12 | 25Â % |